BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931


SEARCH JOBS


Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.


 Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






 Company News
Eisai Inc. (ESALF.PK) Highlights New Research on Melanoma, Breast and Endometrial Cancer at American Society of Clinical Oncology Annual Meeting 5/17/2013 6:42:07 AM    More...
Ricardo Gonzalez Balboa Appointed as General Manager of Eisai Inc. (ESALF.PK) Laboratorios, S. de R.L. de C.V. 5/16/2013 10:23:32 AM    More...
Arena Pharmaceuticals, Inc. (ARNA) Pockets $65 Million From Partner Eisai Inc. (ESALF.PK) After Belviq Approval 5/8/2013 7:40:26 AM    More...
Eisai Company, Ltd. (ESALY.PK) to Establish New Parenteral Facility in China 4/25/2013 8:16:37 AM    More...
GE Healthcare and Eisai Inc. (ESALF.PK) to Partner on Alzheimer's Disease Research 4/24/2013 11:35:55 AM    More...
Arena Pharmaceuticals, Inc. (ARNA) Announces Eisai Inc. (ESALF.PK)'s Submission of BELVIQ® (lorcaserin HCl) Marketing Authorization Application in Mexico 4/1/2013 9:46:35 AM    More...
Eisai Inc. (ESALF.PK) Announces FDA Approval for Aciphex Sprinkle 3/27/2013 7:00:03 AM    More...
Eisai Inc. (ESALF.PK) Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty From Within 3/22/2013 9:52:16 AM    More...
Eisai Inc. (ESALF.PK) Slams German Decision on Fycompa; Takeda Pharmaceutical Co. Ltd. (TKPYY) Files Vedolizumab With European Medicines Agency 3/11/2013 8:44:09 AM    More...
DSM Pharmaceutical Products to Supply Cancer Drug for Eisai Inc. (ESALF.PK) 3/5/2013 7:40:34 AM    More...
12345678